This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
In May 2016, we amended the recommendation on diagnosing latent TB in adults to clarify the sequencing of tests. We also removed references to interferon‑gamma release assay (IGRA) status from recommendations.
The guideline includes recommendations on:
- preventing TB, including in under-served groups
- diagnosing and managing latent TB, including recommendations specifically for children and young people
- diagnosing and managing active TB, including recommendations specifically for children and young people
- drug-resistant TB
- infection control
- case finding and adherence, treatment completion and follow-up, including in under-served groups
Who is it for?
- Healthcare professionals and TB multidisciplinary teams
- Substance misuse services, prisons and immigration removal centres
- Local government and commissioners
- TB control boards, directors of public health and public health consultants
- Public Health England and NHS England
- Voluntary sector workers
- People with TB and their carers
Is this guideline up to date?
We checked this guideline in October 2018 and we are updating the recommendations that focus on diagnosing latent TB in adults.
Guideline development process
This guideline updates and replaces NICE guideline CG117 (March 2011) and NICE guideline PH37 (March 2012).
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.